Citations

Clear

16281 citation(s) found for "Yu, David".

Fatal Complication after Repair of a Congenital Diaphragmatic Hernia Associated with Hepatopulmonary Fusion, Anomalous Right Pulmonary Venous Return, and Azygos Continuation of the Inferior Vena Cava
Hamilton, Joshua W., Jaroszewski, Dawn E. , Notrica, David M.

Mayo Clinic

European Journal of Pediatric Surgery | October 23, 2012 | Volume: 24 | Issue: 04 | Pages: 350-352

10.1055/s-0032-1324695 | PMID 23093429 Get It

High-Risk Long QT Syndrome Mutations in the Kv7.1 (KCNQ1) Pore Disrupt the Molecular Basis for Rapid K+ Permeation
Burgess, Don E. , Bartos, Daniel C. , Reloj, Allison R., Campbell, Kenneth S. , Johnson, Jonathan N. , Tester, David J. , Ackerman, Michael J. , Fressart, Véronique , Guicheney, Pascale , Moss, Arthur J. , Ohno, Seiko , Horie, Minoru , Delisle, Brian P. , Denjoy, Isabelle , Ohno, Seiko , Horie, Minoru

Mayo Clinic

Biochemistry | October 23, 2012 | Volume: 51 | Issue: 45 | Pages: 9076-9085

10.1021/bi3009449 | PMID 23092362 Get It

Improvement in Stroke Risk Prediction: Role of C-Reactive Protein and Lipoprotein-Associated Phospholipase A 2 in the Women's Health Initiative
McGinn, Aileen, Allison, Matthew , Ca, Tianxi, Curb, David, Hendrix, Susan L., Kaplan, Robert C. , Ko, Marcia, Martin, Lisa W. , Xue, Xiaonan , Kaplan, Robert C. , Wassertheil-Smoller, Sylvia W , Eaton, Charles B. , Allison, Matthew A , Warsinger-Martin, Lisa

Mayo Clinic

International Journal of Stroke | October 23, 2012 | Volume: 9 | Issue: 7 | Pages: 902-909

10.1111/j.1747-4949.2012.00860.x | PMID 23088183 Get It

Background Classification of risk of ischemic stroke is important for medical care and public health reasons. Whether addition of biomarkers adds to predictive power of the Framingham Stroke Risk or other traditional risk factors has not been studied in older women. Methods The Hormones and Biomarkers Predicting Stroke Study is a case-control study of blood biomarkers assayed in 972 ischemic stroke cases and 972 controls, nested in the Women's Health Initiative Observational Study of 93 676 postmenopausal women followed for an average of eight-years. We evaluated additive predictive value of two commercially available biomarkers: C-reactive protein and lipoprotein-associated phospholipase A 2 to determine if they added to risk prediction by the Framingham Stroke Risk Score or by traditional risk factors, which included lipids and other variables not included in the Framingham Stroke Risk Score. As measures of additive predictive value, we used the C-statistic, net reclassification improvement, category-less net reclassification improvement, and integrated discrimination improvement index. Results Addition of C-reactive protein to Framingham risk models or additional traditional risk factors overall modestly improved prediction of ischemic stroke and resulted in overall net reclassification improvement of 6·3%, (case net reclassification improvement = 3·9%, control net reclassification improvement = 2·4%). In particular, high-sensitivity C-reactive protein was useful in prediction of cardioembolic strokes (net reclassification improvement = 12·0%; 95% confidence interval 4·3–19·6%) and in strokes occurring in less than three-years (net reclassification improvement = 7·9%, 95% confidence interval 0·8–14·9%). Lipoprotein-associated phospholipase A 2 was useful in risk prediction of large artery strokes (net reclassification improvement = 19·8%, 95% confidence interval 7·4–32·1%) and in early strokes (net reclassification improvement = 5·8%, 95% confidence interval 0·4–11·2%). Conclusions C-reactive protein and lipoprotein-associated phospholipase A 2 can improve prediction of certain subtypes of ischemic stroke in older women, over the Framingham stroke risk model and traditional risk factors, and may help to guide surveillance and treatment of women at risk.
Survival After Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy
Sorajja, Paul , Ommen, Steve R. , Holmes, David R. , Rihal, Charanjit S. , Lennon, Ryan J. , Sorajja, Paul , Dearani, Joseph A. , Rihal, Charanjit S. , Gersh, Bernard J. , Nishimura, Rick A.

Mayo Clinic

Circulation | October 18, 2012 | Volume: 126 | Issue: 20 | Pages: 2374-2380

10.1161/circulationaha.111.076257 | PMID 23076968 Get It

Background— The clinical efficacy of alcohol septal ablation for obstructive hypertrophic cardiomyopathy (HCM) has been demonstrated, but the long-term effects of the procedure remain uncertain. This study examined the survival of patients after septal ablation performed in a tertiary HCM referral center. Methods and Results— We examined 177 patients (mean age, 64 years; 68% women) who underwent septal ablation at our institution. Over a follow-up of 5.7 years, survival free of all mortality was no different than the expected survival for a comparable general population, and similar to that of age- and sex-matched patients who underwent isolated surgical myectomy (8-year survival estimate, 79% versus 79%; P =0.64). For the end point of documented sudden cardiac death or unknown cause of death, the incidence per 100 person-year follow-up was 1.31 (95% confidence interval, 0.60–2.38). Residual left ventricular outflow tract gradient after ablation was an independent predictor of long-term survival free of any death. Conclusions— In this nonrandomized study of carefully selected patients undergoing septal ablation by experienced operators in a tertiary referral HCM center, long-term survival was favorable and similar to that of an age- and sex-matched general population, and to patients undergoing surgical myectomy, as well, without an increased risk of sudden cardiac death.
Unusual Source of Thromboembolism in a Patient with Atrial Fibrillation: Pulmonary Vein Thrombus due to Compressive Para‐Esophageal Hernia
Mulpuru, Siva K. , Krummen, David E. , Narayan, Sanjiv M.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | October 16, 2012 | Volume: 24 | Issue: 5 | Pages: 591-592

10.1111/jce.12034 | PMID 23210526 Get It

Short-Term Monotherapy with IDX184, a Liver-Targeted Nucleotide Polymerase Inhibitor, in Patients with Chronic Hepatitis C Virus Infection
Lalezari, Jacob , Asmuth, David M. , Casiró, Arnaldo, Vargas, Hugo E. , Lawrence, Shannon, Dubuc-Patrick, Gloria, Chen, Jie , McCarville, Joseph, Pietropaolo, Keith, Zhou, Xiao‐Jian, Sullivan-Bolyai, J., Mayers, Douglas L., Vargas, Hugo E , Lalezari, Jay

Mayo Clinic

Antimicrobial Agents and Chemotherapy | October 16, 2012 | Volume: 56 | Issue: 12 | Pages: 6372-6378

10.1128/aac.01521-12 | PMID 23070151 Get It

ABSTRACT IDX184 is a liver-targeted prodrug of 2′-methylguanosine (2′-MeG) monophosphate. This study investigated the safety, tolerability, antiviral activity, and pharmacokinetics of IDX184 as a single agent in treatment-naïve patients with genotype-1 chronic hepatitis C virus (HCV) infection. Forty-one patients with baseline HCV RNA ≥ 5 log 10 IU/ml, alanine aminotransferase (ALT) ≤ 2.5× the upper limit of normal, and compensated liver disease were dosed. Sequential cohorts of 10 patients, randomized 8:2 (active:placebo), received 25, 50, 75, and 100 mg of IDX184 once daily for 3 days, with a 14-day follow-up. There were no safety-related treatment discontinuations or serious adverse events. The adverse events and laboratory abnormalities observed for IDX184- and placebo-treated patients were similar. At the end of the 3-day treatment period, changes from baseline in HCV RNA levels (means ± standard deviations) were −0.5 ± 0.6, −0.7 ± 0.2, −0.6 ± 0.3, and −0.7 ± 0.5 log 10 for the 25-, 50-, 75-, and 100-mg doses, respectively, while viral load remained unchanged for the pooled placebo patients (−0.05 ± 0.3 log 10 ). Patients with genotype-1a and patients with genotype-1b responded similarly. Serum ALT levels decreased, especially at daily doses ≥ 75 mg. During the posttreatment period, plasma viremia and serum aminotransferase levels returned to near pretreatment levels. No resistance mutations associated with IDX184 were detected. Plasma exposure of IDX184 and its nucleoside metabolite 2′-MeG was dose related and low. Changes in plasma viral load correlated with plasma exposure of 2′-MeG. In conclusion, the results from this proof-of-concept study show that small doses of the liver-targeted prodrug IDX184 were able to deliver significant antiviral activity and support further clinical evaluation of the drug candidate.
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
Cairncross, Gregory, Wang, Meihua , Shaw, Edward , Jenkins, Robert B. , Brachman, David, Buckner, Jan C. , Fink, Karen, Souhami, Luís, Laperrière, Normand , Curran, Walter, Mehta, Minesh P. , Mehta, Minesh P

Mayo Clinic

Journal of Clinical Oncology | October 16, 2012 | Volume: 31 | Issue: 3 | Pages: 337-343

10.1200/jco.2012.43.2674 | PMID 23071247 Get It

Purpose Anaplastic oligodendrogliomas, pure (AO) and mixed (anaplastic oligoastrocytoma [AOA]), are chemosensitive, especially if codeleted for 1p/19q, but whether patients live longer after chemoradiotherapy is unknown. Patients and Methods Eligible patients with AO/AOA were randomly assigned to procarbazine, lomustine, and vincristine (PCV) plus radiotherapy (RT) versus RT alone. The primary end point was overall survival (OS). Results Two hundred ninety-one eligible patients were randomly assigned: 148 to PCV plus RT and 143 to RT. For the entire cohort, there was no difference in median survival by treatment (4.6 years for PCV plus RT v 4.7 years for RT; hazard ratio [HR] = 0.79; 95% CI, 0.60 to 1.04; P = .1). Patients with codeleted tumors lived longer than those with noncodeleted tumors (PCV plus RT: 14.7 v 2.6 years, HR = 0.36, 95% CI, 0.23 to 0.57, P < .001; RT: 7.3 v 2.7 years, HR = 0.40, 95% CI, 0.27 to 0.60, P < .001), and the median survival of those with codeleted tumors treated with PCV plus RT was twice that of patients receiving RT (14.7 v 7.3 years; HR = 0.59; 95% CI, 0.37 to 0.95; P = .03). For those with noncodeleted tumors, there was no difference in median survival by treatment arm (2.6 v 2.7 years; HR = 0.85; 95% CI, 0.58 to 1.23; P = .39). In Cox models that included codeletion status, the adjusted OS for all patients was prolonged by PCV plus RT (HR = 0.67; 95% CI, 0.50 to 0.91; P = .01). Conclusion For the subset of patients with 1p/19q codeleted AO/AOA, PCV plus RT may be an especially effective treatment, although this observation was derived from an unplanned analysis.
Response to Letter Regarding Article, “Predictors of Long-Term Survival After Coronary Artery Bypass Grafting Surgery: Results From the Society of Thoracic Surgeons Adult Cardiac Surgery Database (the ASCERT Study)”
Shahian, David M. , O’Brien, Sean M. , Sheng, Shubin , DeLong, Elizabeth R. , Grau‐Sepulveda, Maria V. , Grover, Frederick L., Mayer, John E. , Weiss, Jocelyn M., Klein, Lloyd W. , Shaw, Richard E. , Garratt, Kirk N. , Moussa, Issam , Shewan, Cynthia M., Dangas, George , Edwards, Fred H., Peterson, Eric D. , Jacobs, Jeffrey P. , Weintraub, William S.

Mayo Clinic

Circulation | October 15, 2012 | Volume: 126 | Issue: 16 | Pages: No page available

10.1161/circulationaha.112.130989 Get It

A Novel Disease Gene for Brugada Syndrome
Ishikawa, Taisuke , Marcou, Cherisse A. , Tester, David J. , Ackerman, Michael J. , Crotti, Lia , Schwartz, Peter J. , Park, Jeong-Euy, Nakamura, Kazufumi , Hiraoka, Masayasu , Nakazawa, Kiyoshi, Sakurada, Harumizu, Arimura, Takuro , Makita, Naomasa , Ishikawa, Taisuke , Sato, Akinori , Crotti, Lia , Schwartz, Peter J. , On, Young Keun , Makita, Naomasa , Kimura, Akinori

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | October 13, 2012 | Volume: 5 | Issue: 6 | Pages: 1098-1107

10.1161/circep.111.969972 | PMID 23064965 Get It

Background— Mutations in genes including SCN5A encoding the α-subunit of the cardiac sodium channel (hNav1.5) cause Brugada syndrome via altered function of cardiac ion channels, but more than two-thirds of Brugada syndrome remains pathogenetically elusive. T-tubules and sarcoplasmic reticulum are essential in excitation of cardiomyocytes, and sarcolemmal membrane-associated protein (SLMAP) is a protein of unknown function localizing at T-tubules and sarcoplasmic reticulum. Methods and Results— We analyzed 190 unrelated Brugada syndrome patients for mutations in SLMAP . Two missense mutations, Val269Ile and Glu710Ala, were found in heterozygous state in 2 patients but were not found in healthy individuals. Membrane surface expression of hNav1.5 in the transfected cells was affected by the mutations, and silencing of mutant SLMAP by small interfering RNA rescued the surface expression of hNav1.5. Whole-cell patch-clamp recordings of hNav1.5-expressing cells transfected with mutant SLMAP confirmed the reduced hNav1.5 current. Conclusions— The mutations in SLMAP may cause Brugada syndrome via modulating the intracellular trafficking of hNav1.5 channel.
Triage of patients with acute diverticulitis: are some inpatients candidates for outpatient treatment?
Abbas, Maher A. , Cannom, Rebecca R., Burchette, Raoul J. , Radner, Gazal, Haigh, Philip I. , Etzioni, David A. , Chiu, Vicki Y.

Mayo Clinic

Colorectal Disease | October 12, 2012 | Volume: 15 | Issue: 4 | Pages: 451-457

10.1111/codi.12057 | PMID 23061533 Get It

AbstractAimCurrent recommendations regarding the triage of patients with acute diverticulitis for inpatient or outpatient treatment are vague. We hypothesized that a significant number of patients treated as an inpatient could be managed as an outpatient.MethodA retrospective cohort study was carried out of 639 patients admitted for a first episode of diverticulitis. The diagnosis of acute diverticulitis was confirmed by computed tomography (CT). The endpoints included length of stay, need for surgery, percutaneous drainage and mortality. Patients were considered to have had a minimal hospitalization, defined as survival to discharge without needing a procedure, hospitalization of ≤ 3 days and no readmission for diverticulitis within 30 days after discharge.ResultsOf 639 patients, 368 (57.6%) had a minimal hospitalization. Female gender and CT scan findings of free air/fluid were negatively associated with the likelihood of minimal hospitalization. The presence of an abscess < 3 cm and stranding on CT did not predict the need for a higher level of care. Despite the statistical significance of several patient‐level predictors, the model did not identify patients likely to need only minimal hospitalization.ConclusionMost patients admitted with acute diverticulitis are discharged after minimal hospitalization. Free air/liquid in a patient admitted for acute diverticulitis indicates a more severe clinical course.